RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat adults with H. pylori infection in the United Arab Emirates (UAE) The commercial launch of Talicia triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales Talicia is the leading branded first-line therapy prescribed by U.
S. gastroenterologists [1] for the treatment of H. pylori, a bacterial infection that affects 41% of the UAE population [2] and over 50% of the world's adult population [3] RALEIGH, N.
C. , Aug. 21, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
(Nasdaq: RDHL ) (" RedHill " or the "Company"), a specialty biopharmaceutical company, today announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin) [4] in the United Arab Emirates (UAE) – making it available by prescription to treat adults with Helicobacter pylori ( H. pylori ) infection. The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.
Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori . "We are delighted with the commercial launch of Talicia in the UAE, bringing this important medicine to patients in the region,".